Effects of canagliflozin versus finerenone on cardiorenal outcomes

preview_player
Показать описание
*Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results*

Speaker
Rajiv Agarwal, United States

Panellists
Patrick Mark, United Kingdom
Katherine Tuttle, United States

Moderators
Jennifer Lees, United Kingdom
Kate Stevens, United Kingdom
  1. ERA - European Renal Association
Рекомендации по теме
Effects of canagliflozin 0:54:16

Effects of canagliflozin versus finerenone on cardiorenal outcomes

Jennifer Green, EASD 0:03:41

Jennifer Green, EASD 2022: Finerenone & Empagliflozin in patients with CKD and T2D: CONFIDENCE S...

George Bakris, MD 0:34:04

George Bakris, MD | Use of Finerenone in Patients with Diabetes Who Have Kidney Disease

'FINERENONE' - An 0:01:30

'FINERENONE' - An Insight to the Drug!

Mineralocorticoid Axis in 0:48:12

Mineralocorticoid Axis in Health and Disease- History, Evolution and Clinical Implications

Finerenone: Evaluating and 0:18:41

Finerenone: Evaluating and Understanding this Drug as Treatment

Finerenone Current role 0:50:15

Finerenone Current role in CKD and T2DM Management

Effect of Finerenone 0:01:54

Effect of Finerenone on Chronic Kidney Disease Outcomes in T

FIDELIO BLOCK-CKD Dr. 0:43:31

FIDELIO BLOCK-CKD Dr. Bakris (Chicago)

FIDELIO-DKD, CREDENCE-like outcomes 0:13:59

FIDELIO-DKD, CREDENCE-like outcomes

Finerenone in Patients 0:29:23

Finerenone in Patients with Diabetes and CKD

DKD treatment update: 0:18:00

DKD treatment update: SGLT2 inhibitors and finerenone | Ian de Boer & Amrit Lamba

Nonsteroidal mineralocorticoid receptor 0:50:00

Nonsteroidal mineralocorticoid receptor antagonists & cardiorenal outcomes in chronic kidney dis...

Dr. Per-Hernik Groop 0:17:59

Dr. Per-Hernik Groop - New Ways to Understand Kidney Disease in Diabetes

Professor David Wheeler 0:30:05

Professor David Wheeler - Renoprotective effects of SGLT2 inhibitors

Finerenone The 0:15:29

Finerenone The new block buster for CKD with additional CV benefits

SGLT2 Inhibitors: Can 0:49:14

SGLT2 Inhibitors: Can these drugs slow the progression of chronic kidney disease?

Finerenone Investor-Webinar 0:56:20

Finerenone Investor-Webinar

Nephrology Grand Rounds: 0:58:38

Nephrology Grand Rounds: SGLT2 Inhibitors

CKD E-Learning - 0:46:01

CKD E-Learning - SGLT-2 inhibitors and CKD - 05.19.21

Endocrine case series 0:36:12

Endocrine case series S01E01: How to protect the kidney in diabetes kidney disease ?

Role of Mineralocorticoid 0:53:13

Role of Mineralocorticoid Receptor Antagonist in the treatment of DKD ft. Sylvia E. Rosas, MD, MSCE

SGLT2 Inhibitors in 0:09:06

SGLT2 Inhibitors in Chronic Kidney Disease

Insights from the 0:14:25

Insights from the FIGARO-DKD and FIDELIO-DKD trials - English Language - Dr. Gawad